This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Learn why balancing short and long term goals leads to steadier progress and fewer stressful financial decisions.
28,657 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Amazon's latest earnings highlighted a bold AI bet and a hefty capex agenda. This article breaks down what it means f...
Millions rely on Social Security for steady income, but errors can trim benefits. This article explains how social se...
As AI accelerates, two chipmakers stand out for very different reasons. This analysis weighs whether broadcom stock b...
A major private markets investor recently exited its position in Paymentus Holdings, shedding a sizable stake in a mo...
Solana and XRP sit at the center of a debate about which blockchain will power the next wave of tokenized real-world ...
Explore what Q1 2026 earnings could mean for American Eagle Outfitters. This guide breaks down revenue, margins, and ...
A new wave of tech IPOs is poised to influence index funds and passive strategies. Learn what it means for your portf...
SpaceX finally going public would rewrite who can own a piece of the rocket company. This guide breaks down the IPO b...
A fresh AI-related order sparked a sharp move in Aehr Test Systems stock, with investors pricing in potential growth ...
A tempting promise of free phones drew unsuspecting customers into a mailbox scam that police say ended with dozens o...
Retirees face a tricky balance: can a mortgage under 6% really make buying a home worthwhile? This guide weighs the m...